A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma

We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youngwoon, Kim, Ka Young, Lee, Su Hyun, Chung, Yoon Yung, Yahng, Seung-Ah, Lee, Sung-Eun, Park, Gyeongsin, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422711/
https://www.ncbi.nlm.nih.gov/pubmed/22916049
http://dx.doi.org/10.4110/in.2012.12.3.126
Descripción
Sumario:We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when free kappa light chains were noticeably reduced in the serum. After discontinuation of bortezomib, liver enzymes recovered gradually to baseline. Then, the patient was started on a thalidomide-containing regimen, which he was able to tolerate well. The patient achieved complete remission prior to autologous stem cell transplantation (ASCT). The patient underwent ASCT without occurrence of further liver toxicity.

Ejemplares similares